Search
Displaying 371–380 of 693 for “retinal diseases”
-
First Patient Receives ProQR’s Emerging USH2A Therapy in Clinical Trial
Research NewsProQR, a developer of RNA therapies in the Netherlands, announced that the first clinical-trial participant has received its emerging treatment, which targets retinitis pigmentosa and Usher syndrome caused by mutations in exon 13 of the USH2A gene.
-
Clinical Trial Authorized in the U.S. for Emerging LCA 10 Therapy
Research NewsProQR, a biotechnology company in the Netherlands, has received authorization from the U.S. Food and Drug Administration to start a Phase I/II clinical trial for its therapy known as QR-110
-
First Patient Treated in XLRP Gene Therapy Clinical Trial
Research NewsThe Nightstar gene therapy involves injection of healthy copies of RPGR underneath the retina.
-
A Surprising Number of Carrier Females are Affected by X-Linked Retinitis Pigmentosa
Research News40 percent of genetically tested XLRP carriers showed a definitive abnormality in at least one of three visions tests.
-
Taking Their Story of Vision Loss on the Road
Beacon StoriesRollie and Sandie Purvis, parents of two sons with choroideremia, describe their sons’ film project, “Driving Blind.”
-
- Sep 9, 2026 - Sep 11, 2026
- 5:00 p.m. - 1:00 p.m.
- 10950 N. Torrey Pines Road, La Jolla, CA 92037
Foundation EventThe Foundation Fighting Blindness, together with the Nixon Visions Foundation, invites you to join a free, in-person workshop bringing together individuals and families affected by PRPH2 and associated retinal diseases, along with researchers, physicians, and industry partners.
-
Seen at Last: How Love Is Blind Gave Madison a Platform for RP
Beacon StoriesFrom reality TV to real-world impact, Madison Maidenberg turned her Love Is Blind spotlight into a platform for blinding diseases. As a contestant living with retinitis pigmentosa, she’s challenging misconceptions about blindness and becoming a powerful voice for the blind and low vision community.
-
VeonGen Reports Promising Clinical Progress for Stargardt Disease Gene Therapy
Research NewsVG801 shows sustained vision improvements through 12 months with favorable safety profile
-
Belite Bio to Seek FDA Approval for its Stargardt Disease Drug
Research NewsTinlarebant slowed disease progression by 36 percent in the Dragon Phase 3 clinical trial.
-
Sepul Bio’s LCA10 RNA Therapy Moves into Phase 3 Clinical Trial
Research NewsThe emerging therapy improved vision for some participants in an earlier clinical trial.
